AETHLON MEDIC.NEW DL-001
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, … Read more
AETHLON MEDIC.NEW DL-001 (EJU) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.279x
Based on the latest financial reports, AETHLON MEDIC.NEW DL-001 (EJU) has a cash flow conversion efficiency ratio of -0.279x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.87 Million) by net assets (€6.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AETHLON MEDIC.NEW DL-001 - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how AETHLON MEDIC.NEW DL-001's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AETHLON MEDIC.NEW DL-001 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AETHLON MEDIC.NEW DL-001 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OCCID.PETROL CORP
MU:OPC
|
0.105x |
|
Megaron SA
WAR:MEG
|
0.013x |
|
BENCHMARK ELECTRS
MU:BMU
|
0.035x |
|
MONDELEZ INT-A - Dusseldorf Stock Exchang
DU:KTF
|
0.047x |
|
Binah Capital Group, Inc. Warrants
NASDAQ:BCGWW
|
0.051x |
|
First Colombia Gold Corp
PINK:FCGD
|
0.064x |
|
PROPHECY DEFI INC.
F:V8M
|
N/A |
|
International Stem Cell Corp
OTCQB:ISCO
|
-0.013x |
Annual Cash Flow Conversion Efficiency for AETHLON MEDIC.NEW DL-001 (2020–2025)
The table below shows the annual cash flow conversion efficiency of AETHLON MEDIC.NEW DL-001 from 2020 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €5.12 Million | €-7.65 Million | -1.492x | +15.06% |
| 2024-03-31 | €5.77 Million | €-10.13 Million | -1.757x | -151.91% |
| 2023-03-31 | €15.06 Million | €-10.51 Million | -0.697x | -21.32% |
| 2022-03-31 | €16.99 Million | €-9.77 Million | -0.575x | +21.03% |
| 2021-03-31 | €9.29 Million | €-6.76 Million | -0.728x | -29.93% |
| 2020-03-31 | €9.28 Million | €-5.20 Million | -0.560x | -- |